Pharmacological treatment options for mast cell activation disease.

This resource reviews pharmacological treatment options for mast cell activation disease (MCAD), a spectrum of disorders ranging from mast cell activation syndrome (MCAS) to systemic mastocytosis (SM) and mast cell leukemia (MCL). MCAD is characterized by excessive mediator release from mast cells and, in some severe cases, mast cell proliferation causing organ failure. The article highlights current treatments focused on symptom control through managing mediator effects and discusses advanced therapies for aggressive conditions targeting mast cell proliferation using kinase inhibitors. It also explores potential future therapies, including targeted treatments that inhibit mutant protein variants and specific mast cell surface antigens. The goal is to enhance clinician awareness and ability to diagnose and treat these complex and diverse conditions effectively.